Pegulicianine acetate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for pegulicianine acetate and what is the scope of patent protection?
Pegulicianine acetate
is the generic ingredient in one branded drug marketed by Lumicell and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Pegulicianine acetate has twenty-three patent family members in seven countries.
One supplier is listed for this compound.
Summary for pegulicianine acetate
| International Patents: | 23 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | pegulicianine acetate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for pegulicianine acetate
Generic Entry Date for pegulicianine acetate*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for pegulicianine acetate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for pegulicianine acetate
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2014152797 | ⤷ Sign Up | |
| Japan | 6478971 | ⤷ Sign Up | |
| European Patent Office | 2435096 | PROCÉDÉS ET SYSTÈMES DESTINÉS À IDENTIFIER DE MANIÈRE SPATIALE DES CELLULES ANORMALES (METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS) | ⤷ Sign Up |
| Japan | 2023120180 | 医用撮像装置と使用方法 (MEDICAL IMAGING DEVICE AND USE METHOD) | ⤷ Sign Up |
| Australia | 2016277654 | METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
